Uncategorized Why Eli Lilly closed its research center in China?

Why Eli Lilly closed its research center in China?

On September 7th, Eli Lilly, the US Pharma giant, closed its Zhangjiang research center in China, just a month after GlaxoSmithKline (GSK)’s ended its neuroscience unit in Shanghai. Andrew Hodge, the president and general manager of Lilly China, announced the news to the Chinese employees. He stressed that the move is slated to optimize the …

Read Article Read More

Uncategorized A look of the major listed cell immunotherapy companies in China

A look of the major listed cell immunotherapy companies in China

The summer of 2017 is the start of the golden age for cell immunotherapy. Since the end of June, there is no shortage of attention in this red-hot market. On June 29th, Sanpower Group, the Chinese pharma giant, has announced its acquisition of Dendreon with $819 million. The core product of the latter is the …

Read Article Read More

Uncategorized Chinese biopharmas are marching into the United States market: A look at all US-listed Chinese biologics companies

Chinese biopharmas are marching into the United States market: A look at all US-listed Chinese biologics companies

On September 21st, Zai Lab, the Chinese biopharma start-up, has officially listed in the United States Nasdaq global market, bagged a total of $150 million. On the same day, its stock rose 55.17%, amount to $27.93 per share. Zai Lab is not the first Chinese biopharmaceutical company which has completed an IPO in the United …

Read Article Read More

Uncategorized Medical laboratory diagnostics giants are facing a new round of expansions

Medical laboratory diagnostics giants are facing a new round of expansions

KingMed Diagnostics, Guangzhou based medical laboratory diagnostics giant, has officially listed in the Shanghai Stock Exchange on September 8th, marking the beginning of the Chinese third-party medical diagnostics industry holding hands with the capital market. KingMed Diagnostics, established in 2003, is an independent medical laboratory specializing in third-party medical testings and pathological diagnoses. Its main …

Read Article Read More

Uncategorized The 3 Important Factors To Consider When Commercializing The CAR-T Therapy

The 3 Important Factors To Consider When Commercializing The CAR-T Therapy

Last month, Novartis’s CAR-T cell therapy CTL-019 has unanimously (10-0) won a recommended approval from FDA advisory committee to treat pediatric, young adult r/r B-cell ALL, marking one big step closer to reaching patients. The vote represents a pivotal milestone for this class of experimental treatment. The FDA is expected to make a final decision …

Read Article Read More

Uncategorized Where Does The Future Lies In The Chinese CAR-T Market?

Where Does The Future Lies In The Chinese CAR-T Market?

In 2017, a series of events have drawn national and international attentions to CAR-T therapy, making it one of the hottest topic of the year. In January, Shanghai Fosun and Kite Pharma has formed a joint venture, with each holding 50% stake. In February, Juno has announced to discontinue its JCAR015 trail and began to …

Read Article Read More

Uncategorized The 4 Trends of In Vitro Diagnostics in China

The 4 Trends of In Vitro Diagnostics in China

In recent years, merger and acquisition (M&A) has been the dominant theme in the Chinese healthcare and pharmaceutical industry, especially in the field of in vitro diagnostics (IVD). A number of companies have undergone acquisitions and this trend will continue to grow in 2018. This integration phenomenon has raised new requirements and challenges for large customer-oriented central …

Read Article Read More